However, we consider that to benefit as a diagnostic tumor marker in the clinical setting, HE-4 should be investigated further in tissue expression and at serum levels in benign and malignant lung diseases, as well as the substrates of different lung cancers. The gene discussed is WFDC2; the disease is lung carcinoma.